LMW Heparin: Relationship Between Antithrombotic and Anticoagulant Effects

  • T. W. Barrowcliffe
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 313)


LMW heparin is now becoming a well established alternative to unfractionated heparin (UFH), particularly for the prophylaxis of deep vein thrombosis, where the convenience of a single injection a day, instead of two or three as for UFH, is a decided advantage. Whilst the mechanisms of the anticoagulant actions of heparin and LMW heparin at the molecular level are now well understood, there is still some uncertainty and controversy over the mechanisms of their antithrombotic effect in vivo, and in particular about the relevance of the various in vitro anticoagulant assays to their in vivo actions.


Thrombin Generation Anticoagulant Activity Antithrombotic Action Anti Thrombotic Effect Anti Thrombotic Action 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    E. A. Johnson, T. B. L. Kirkwood, Y. Stirling, J. L. Perez-Requejo, G. I. C. Ingram, D. R. Bangham, and M. Brozovic. Four heparin preparations: anti-Xa potentiating effect of heparin after subcutaneous injection. Thromb. Haemost. 35:586–591 (1976).PubMedGoogle Scholar
  2. 2.
    P. B. Ostergaard, B. Nilsson, D. Bergvist, U. Hedner, and P. C Pederson. The effect of low molecular weight heparin on experimental thrombosis and haemostasis — the influence of production method. Thromb. Res. 45:739–749 (1987).PubMedCrossRefGoogle Scholar
  3. 3.
    T. W. Barrowcliffe, A. D. Curtis, T. P. Tomlinson, A. R. Hubbard, E. W. Johnson, and D. P. Thomas. Standardisation of low molecular heparins: a collaborative study. Thromb. Haemost. 54:675–679 (1985).PubMedGoogle Scholar
  4. 4.
    T. W. Barrowcliffe, A. D. Curtis, E. A. Johnson, and D. P. Thomas. An International Standard for low molecular weight heparin. Thromb. Haemost. 60:1–7 (1988).PubMedGoogle Scholar
  5. 5.
    M. W. Pomerantz, and W. G. Owen. A catalytic role for heparin. Evidence for a ternary complex of heparin cofactor thrombin and heparin. Biochim. Biophys. Acta 535:66–77 (1978).PubMedCrossRefGoogle Scholar
  6. 6.
    D. A. Lane, J. Denton, A. M. Flynn, L. Thunberg, and U. Lindahl. Anticoagulant activities of heparin oligosaccharides and their neutralization by platelet factor 4. Biochem. J. 218:725–732 (1984).PubMedGoogle Scholar
  7. 7.
    T. W. Barrowcliffe, and Y. Le Shirley. The effect of calcium chloride on anti-Xa activity of heparin and its molecular weight fractions. Thromb. Haemost. 62:950–954 (1989).PubMedGoogle Scholar
  8. 8.
    V. Ellis, M. F. Scully, and V. V. Kakkar. The relative molecular mass dependence of the anti-factor Xa properties of heparin. Biochem. J. 238:329–333 (1986).PubMedGoogle Scholar
  9. 9.
    T. W. Barrowcliffe, S. J. Havercroft, G. Kemball-Cook, and U. Lindahl. The effect of Ca2+, phospholipid, and Factor V on the anti-(Factor Xa) activity of heparin and its high-affinity oligosaccharides. Biochem. J. 243:31–37 (1987).PubMedGoogle Scholar
  10. 10.
    P. Schoen, T. Lindhout, G. Willems, and H. C. Hemker. Antithrombin III-dependent anti-prothrombinase activity of heparin and heparin fragments. J. Biol. Chem. 264:10002–10007 (1989).PubMedGoogle Scholar
  11. 11.
    M. J. Griffith. Kinetics of the heparin-enhanced antithrombin III/thrombin reaction. J. Biol. Chem. 257:7360–7365 (1982).PubMedGoogle Scholar
  12. 12.
    F. A. Ofosu, M. A. Blajchman, G. J. Modi, L. M. Smith, M. R. Buchanan, and J. Hirsh. The importance of thrombin inhibition for the expression of the anticoagulant activity of heparin, dermatan sulphate, low molecular weight heparin and pentosan polysulphate. Brit. J. Haem. 60:695–704 (1985).CrossRefGoogle Scholar
  13. 13.
    H. C. Hemker. The mode of action of heparin in plasma, in: “Thrombosis and Haemostasis,” M. Verstraete, J. Vermylen, R. Lijnen, J. Arnout, eds., Leuven University Press, Leuven (1987).Google Scholar
  14. 14.
    T. W. Barrowcliffe, and D. P. Thomas. Anticoagulant activities of heparin and fragments, in: “Heparin and Related Polysaccharides,” F. A. Ofosu, I. Danishefsky, J. Hirsh, eds., Ann. New York Acad. Sci. 556:132–145 (1989).Google Scholar
  15. 15.
    E. Gray, J. Watton, S. Cesmeli, T. W. Barrowcliffe, and D. P. Thomas. Experimental studies on a recombinant hirudin, CGP 39393. Thromb. Haemost. 65:355–359 (1991).PubMedGoogle Scholar
  16. 16.
    D. P. Thomas, T. W. Barrowcliffe, R. E. Merton, J. Stocks, J. Dawes, and D. S. Pepper. In vivo release of anti-Xa clotting activity by a heparin analogue. Thromb. Res. 17:831–840 (1980).PubMedCrossRefGoogle Scholar
  17. 17.
    E. Gray, G. Bengtsson-Olivecrona, T. Olivecrona, and T. W. Barrowcliffe. The anti-Xa activity of human hepatic triglyceride lipase. J. Lab. Clin. Med. 109:653–659 (1987).PubMedGoogle Scholar
  18. 18.
    M. Sandset, U. Abildgaard, and M. L. Larsen. Heparin induces release of extrinsic pathway inhibitor (EPI). Thromb. Res. 50:803–813 (1988).PubMedCrossRefGoogle Scholar
  19. 19.
    D. P. Thomas. Pathogenesis of venous thrombosis, in: “Haemostasis and Thrombosis,” A. L. Bloom, D. P. Thomas, eds., Churchill Livingstone, Edinburgh (1987).Google Scholar
  20. 20.
    S. Wessler. Thrombosis in the presence of vascular stasis. Amer. J. Med. 33:648–666 (1962).PubMedCrossRefGoogle Scholar
  21. 21.
    D. P. Thomas, R. E. Merton, W. E. Lewis, and T. W. Barrowcliffe. Studies in man and experimental animals of a low molecular weight heparin fraction. Thromb. Haemost. 45:214–218 (1981).PubMedGoogle Scholar
  22. 22.
    E. Holmer, C. Mattson, and S. Nilsson. Anticoagulant and antithrombotic effects of heparin and low molecular weight heparin fragments in rabbits. Thromb. Res. 25:475–485 (1982).PubMedCrossRefGoogle Scholar
  23. 23.
    D. Bergvist, B. Nilsson, U. Hedner, P. C. Petersen, and P. B. Ostergaard. The effect of heparin fragments of different molecular weights on experimental thrombosis and haemostasis. Thromb. Res. 38:589–601 (1985).CrossRefGoogle Scholar
  24. 24.
    V. Diness, J. I. Nielsen, P. C. Perdersen, K. H. Wolffbrandt, and P. B. Ostergaard. A comparison of the antithrombotic and haemorrhagic effects of a low molecular weight heparin (LHN-1) and conventional heparin. Thromb. Hasmost. 55:410–414 (1986).Google Scholar
  25. 25.
    D. P. Thomas, R. E. Merton, T. W. Barrowcliffe, L. Thunberg, and U. Lindahl. Effects of heparin oligosaccharides with high affinity for antithrombin III in experimental venous thrombosis. Thromb. Haemost. 47:244–248 (1982).PubMedGoogle Scholar
  26. 26.
    P. A. Ockelford, C. J. Carter, L. Mitchell, and J. Hirsh. Discordance between the anti-Xa activity and the antithrombotic activity of an ultra-low molecular weight heparin fraction. Thromb. Res. 28:401–409 (1982).PubMedCrossRefGoogle Scholar
  27. 27.
    T. W. Barrowcliffe, R. E. Merton, S. J. Havercroft, L. Thunberg, U. Lindahl, and D. P. Thomas. Low-affinity heparin potentiaties the action of high-affinity heparin oligosaccharides. Thromb. Res. 34:125–133 (1984).PubMedCrossRefGoogle Scholar
  28. 28.
    C. Mattson, M. Palm, K. Soderberg, and E. Holmer. Antithrombotic effect of heparin oligosaccharides. Ann. New York Acad. Sci. 556:323–332 (1989).CrossRefGoogle Scholar
  29. 29.
    J. M. Walenga, M. Petitou, J. C. Lormeau, M. Samama, J. Fareed, and J. Choay. Antithrombotic activity of a synthetic heparin pentasaccharide in a rabbit stasis thrombosis model using different thrombogenic challenges. Thromb. Res. 46:187–198 (1987).PubMedCrossRefGoogle Scholar
  30. 30.
    D. P. Thomas, R. E. Merton, E. Gray, and T. W. Barrowcliffe. The relative antithrombotic effectiveness of heparin, a low molecular weight heparin and a pentasaccharide fragment in an animal model. Thromb. Haemost. 61:204–207 (1989).PubMedGoogle Scholar
  31. 31.
    J. Amar, C. Caranobe, P. Sie, and B. Boneu. Antithrombotic potencies of heparins in relation to their antifactor Xa and antithrombin activities: an experimental study in two models of thrombosis in the rabbit. Brit. J. Haemat. 76:94–100 (1990).PubMedCrossRefGoogle Scholar
  32. 32.
    F. A. Ofosu, F. Fernandez, N. Anvari, C. Caranobe, F. Dol, Y. Cadroy, M. Petitou, J. Mardiguain, P. Sie, and B. Boneu. Further studies on the mechanisms for the antithrombotic effects of sulphated polysaccharides in rabbits. Thromb. Haemost. 60:188–192 (1988).PubMedGoogle Scholar
  33. 33.
    H. Ireland, D. A. Lane, A. Flynn, A. C. Pegrum, and J. R. Curtis. Low molecular weight heparin in haemodialysis for chronic renal failure: dose finding study of CY222. Thromb. Haemost. 59:240–247 (1988).PubMedGoogle Scholar
  34. 34.
    C. J. Tew, D. A. Lane, E. Thompson, H. Ireland, and J. R. Curtis. Relationship between ex vivo anti-proteinase (factor Xa and thrombin) assays and in vivo anticoagulant effect of very low molecular weight heparin, CY222. Brit. J. Haemat. 70:335–340 (1988).PubMedCrossRefGoogle Scholar
  35. 35.
    J. J. J. Borm, R. Krediet, A. Sturk, and J. W. ten Cate. Heparin versus low molecular weight heparin K2165 in chronic haemodialysis patients: a randomised cross-over study. Haemostasis 16:Suppl 2, 59–68 (1986).PubMedGoogle Scholar
  36. 36.
    B. Ljungberg, M. Blomback, H. Johnsson, and L. E. Lins. A single dose of low molecular weight heparin fragment for anticoagulation during haemodialysis. Clin. Nephrol. 27:31–35 (1987).PubMedGoogle Scholar
  37. 37.
    J. Albada, H. K. Nieuwenhuis, and J. J. Sixma. Treatment of acute venous thromboembolism with low molecular weight heparin (Fragmin). Results of a double-blind randomised study. Circulation 80:935–940 (1989).PubMedCrossRefGoogle Scholar
  38. 38.
    M. N. Levine, A. Planes, J. Hirsh, M. Goodyear, N. Vochelle, and M. Gent. The relationship between anti-Factor Xa level and clinical outcome in patients receiving Enoxaparine low molecular weight heparin to prevent deep vein thrombosis after hip replacement. Thromb. Haemost. 62:940–944 (1989).PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1992

Authors and Affiliations

  • T. W. Barrowcliffe
    • 1
  1. 1.National Institute for Biological Standards and ControlPotters BarUK

Personalised recommendations